Canadian Journal of Diabetes最新文献

{"title":"Screening and Diagnosis of Chronic Kidney Disease in Adults Living With Diabetes: A Retrospective Cohort Study Using the Canadian Primary Care Sentinel Surveillance Network","authors":"Jason E. Black MSc ,&nbsp;David J.T. Campbell MD, PhD ,&nbsp;Paul E. Ronksley PhD ,&nbsp;Kerry A. McBrien MD, MPH ,&nbsp;Tyler S. Williamson PhD","doi":"10.1016/j.jcjd.2024.08.001","DOIUrl":"10.1016/j.jcjd.2024.08.001","url":null,"abstract":"<div><h3>Objectives</h3><div>In Canada, regional evaluations of screening practices for chronic kidney disease (CKD) among people with diabetes highlight areas for improvement; however, national estimates are notably absent. Estimates of CKD incidence often discount the expected decline in estimated glomerular filtration rate (eGFR) associated with age; age-adaptive thresholds may help account for this. We describe the frequency of screening and diagnosis of CKD among adults with diabetes from a nationally representative primary care cohort.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, we used electronic medical record data from the Canadian Primary Care Sentinel Surveillance Network. We followed adult patients (≥18 years of age) with diabetes without CKD at baseline for 5 years starting in 2014. We determined the frequency of urine albumin-to-creatinine ratio (uACr) and/or eGFR testing over time. We identified incident CKD diagnoses based on eGFR measurements using fixed-threshold and age-adaptive definitions and quantified the incidence proportion and rate.</div></div><div><h3>Results</h3><div>We analyzed records from 37,604 patients with diabetes. Only 13% of patients had yearly eGFR and uACr testing for CKD, although roughly 60% had non-yearly use of both tests in 5 years. eGFR testing was performed more frequently than uACr testing (94.1% vs 76.6% having testing over follow-up). We found increased incidence proportions (14.6% vs 6.0%) and rates (33.1 vs 13.4 diagnoses per 1,000 person-years) of CKD using the fixed-threshold compared with age-adaptive definition.</div></div><div><h3>Conclusions</h3><div>Our study presents the first national understanding of screening practices for CKD among people with diabetes in Canada. Specifically, increased use of uACr testing should be encouraged for early detection of changes in kidney function.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 487-492.e3"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141972461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ramadan-Induced Lifestyle Changes: Effects on Sleep and Physical Activity in Nonfasting Individuals With Type 1 Diabetes","authors":"Warda Lahouel MSc ,&nbsp;Mohamed Amine Bouzid PhD ,&nbsp;Faten Hadj Kacem MD ,&nbsp;Omar Hammouda PhD ,&nbsp;Haitham Rebai Pr ,&nbsp;Hamdi Frikha MD ,&nbsp;Mohamed Abid MD ,&nbsp;Mouna Mnif MD ,&nbsp;Sémah Tagougui PhD","doi":"10.1016/j.jcjd.2024.09.146","DOIUrl":"10.1016/j.jcjd.2024.09.146","url":null,"abstract":"<div><h3>Objectives</h3><div>In this study, we aimed to identify sleep patterns, physical fitness, and barriers to physical activity (PA) during Ramadan observance in a cohort of nonfasting individuals with type 1 diabetes (T1D).</div></div><div><h3>Methods</h3><div>Sixty-one nonfasting individuals with T1D, age 28.34±9.43 years (ranging from 15 to 54 years), completed questionnaires before and during Ramadan. The questionnaires included 3 assessment instruments: the Barriers to Physical Activity in Type 1 Diabetes (BAPAD1), the Pittsburgh Sleep Quality Index (PSQI), and the International Physical Activity Questionnaire.</div></div><div><h3>Results</h3><div>During Ramadan, there was no significant change in BAPAD1 scores compared to before Ramadan (p=0.378). The primary barriers encompassed hypoglycemia risk, work schedules, diabetes control, and fatigue. Moreover, subjective sleep quality deteriorated during Ramadan compared to the pre-Ramadan period (p&lt;0.001). Sleep duration decreased by 58 minutes (p&lt;0.01) and was associated with later bedtimes and more awakenings. There was a notable decrease in PA levels (p=0.042), particularly for vigorous activities (p=0.017), whereas sedentary time showed a significant increase (p=0.008).</div></div><div><h3>Conclusions</h3><div>Ramadan observance did not affect barriers to PA in individuals with T1D despite alteration of sleep patterns and PA levels. Lifestyle alterations associated with Ramadan observance significantly impact individuals with T1D who are not fasting, resulting in reduced PA, shortened sleep duration, and increased sedentary time.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 531-538"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women’s and Partners’ Experiences With a Closed-loop Insulin Delivery System to Manage Type 1 Diabetes in the Postpartum Period","authors":"Maira Quintanilha RD, PhD ,&nbsp;Jennifer M. Yamamoto MD, MSc ,&nbsp;Breanne Aylward MSc ,&nbsp;Denice S. Feig MD, MSc ,&nbsp;Patricia Lemieux MD ,&nbsp;Helen R. Murphy MD ,&nbsp;Ronald J. Sigal MD, MPH ,&nbsp;Josephine Ho MD, MSc ,&nbsp;Heidi Virtanen MSc ,&nbsp;Susan Crawford MSc ,&nbsp;Lois E. Donovan MD, FRCPC ,&nbsp;Rhonda C. Bell PhD","doi":"10.1016/j.jcjd.2024.08.005","DOIUrl":"10.1016/j.jcjd.2024.08.005","url":null,"abstract":"<div><h3>Objectives</h3><div>Closed-loop insulin delivery has the potential to offer women with type 1 diabetes a break from intense diabetes self-care efforts postpartum. Our aim in this study was to explore the views and opinions of hybrid closed-loop users and their partners in the first 24 weeks postpartum.</div></div><div><h3>Methods</h3><div>This qualitative study was embedded in a controlled study of women with type 1 diabetes randomized to closed-loop insulin delivery (MiniMed 670G or 770G; Medtronic, Minneapolis, Minnesota, United States) or sensor-augmented pump use for 1 to 11 weeks 6 days postpartum, with all on closed-loop delivery from 12 to 24 weeks postpartum. Semistructured interviews were conducted with 16 study participants and their partners at 12 and 24 weeks postpartum. Thematic analyses were used to examine participants’ and partners’ experiences.</div></div><div><h3>Results</h3><div>Participants’ positive perceptions of closed-loop use related to reduced hypoglycemia, in contrast to previous experiences with nonautomated insulin delivery. These perceptions were balanced against frustrations with the system, allowing blood glucose levels to be higher than desired. Closed-loop use did not influence infant feeding choice, but infant feeding and care impacted participants’ diabetes management. Partners expressed uncertainty about the closed loop taking away control from participants who were highly skilled with diabetes self-management.</div></div><div><h3>Conclusions</h3><div>Participants reported that closed-loop insulin delivery resulted in less time spent in hypoglycemia when compared with the previously used nonautomated delivery. However, participants desired a greater understanding of the workings of the closed-loop algorithm. Our study provides potential users with realistic expectations about the experience with the MiniMed 670G or 770G closed-loop system in the postpartum period.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 502-509.e2"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemic Management in Diabetic Foot Ulcers: A Comparative Analysis of Wound and Wound-free Periods in Adults With Type 1 and Type 2 Diabetes","authors":"Salman Z. Bhat MD ,&nbsp;Noora Al-Hajri MD, MPH ,&nbsp;Sarah Kanbour MD ,&nbsp;Muzzammil Ahmadzada BS ,&nbsp;Alexander Borovoy BA ,&nbsp;Mohammed S. Abusamaan MD, MPH ,&nbsp;Joseph K. Canner MHS ,&nbsp;Caitlin Nass NP ,&nbsp;Ronald L. Sherman DPM ,&nbsp;Kathryn F. Hines PA-C, MS, MBA ,&nbsp;Caitlin W. Hicks MD, MS ,&nbsp;Christopher J. Abularrage MD ,&nbsp;Nestoras Mathioudakis MD, MHS","doi":"10.1016/j.jcjd.2024.08.007","DOIUrl":"10.1016/j.jcjd.2024.08.007","url":null,"abstract":"<div><h3>Objective</h3><div>Our aim in this study was to determine whether there are differences in glycemia during wound and wound-free states among individuals with diabetes at a multidisciplinary diabetic foot and wound clinic from 2012 to 2019.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of prospectively collected data over 7.4 years from the Johns Hopkins Multidisciplinary Diabetic Foot and Wound Clinic. Participants with diabetic foot ulcers were observed during at least one wound period and one wound-free period and had at least one glycated hemoglobin (A1C) measurement in both a wound period and a wound-free period. The A1C measurements were aggregated and summarized across wound and wound-free periods, and compared using the Wilcoxon matched-pairs signed rank test.</div></div><div><h3>Results</h3><div>Two hundred six eligible participants with a total of 623 wounds were included in this analysis. Participants were followed for a median period of 2.4 years (876 days). There were no significant differences in mean, minimum, and maximum A1C between the aggregate wound and wound-free periods, with median values of 7.6% (interquartile range [IQR] 6.6% to 9.1%) and 7.5% (IQR 6.6% to 9.1%) for mean A1C (p=0.43), 6.9% (IQR 6.0% to 8.0%) and 6.8% (6.0% to 8.1%) for minimum A1C (p=0.78), and 8.6% (IQR 7.1% to 10.9%) and 8.5% (IQR 7.0% to 10.7%) for maximum A1C (p=0.06) in the wound and wound-free periods, respectively.</div></div><div><h3>Conclusions</h3><div>This retrospective study shows similar levels of A1C during wound and wound-free periods; however, given the limitations of missing A1C and small sample size, further studies leveraging continuous glucose monitoring are needed to determine whether glycemia worsens in the setting of a DFU.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 517-523.e2"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Experiences With Hospitalization Due to Diabetes in Alberta, Canada: A Cohort Study Using Survey and Administrative Data","authors":"Kyle A. Kemp PhD ,&nbsp;Paul Fairie PhD ,&nbsp;Maria J. Santana PhD, MPharm, MRPharmS","doi":"10.1016/j.jcjd.2024.10.005","DOIUrl":"10.1016/j.jcjd.2024.10.005","url":null,"abstract":"<div><h3>Objectives</h3><div>Individuals living with diabetes are often hospitalized. Despite this, little is known about their experiences with hospital care. In this study, we examined the comprehensive experiences of patients hospitalized due to diabetes in Alberta, Canada, and compared them with those of patients hospitalized for other chronic conditions.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study that linked survey data with inpatient records. Survey data were collected using the Canadian Patient Experiences Survey–Inpatient Care (CPES-IC) instrument. Results from 37 questions were classified as percent in “top box,” which reflects the most positive answer choice. We also examined the association between overall experience and demographic and clinical factors among those living with diabetes.</div></div><div><h3>Results</h3><div>Over a 7-year period, 12,593 surveys (2,288 with diabetes and 10,305 with other chronic conditions) were obtained. Patients hospitalized due to diabetes had lower “top-box” scores on 24 questions, higher scores on 3 questions, and the remaining 10 questions showed no difference between groups. Those hospitalized due to diabetes indicated potential areas for improvement. These included receiving information about their condition and about the admission process, the nighttime quietness of their hospital room, being informed about possible side effects of new medications, and pain control. Overall experience was also shown to vary according to demographic and clinical factors.</div></div><div><h3>Conclusions</h3><div>We found that individuals hospitalized due to diabetes reported lower experience scores than those hospitalized due to other chronic conditions. Our findings may be used to develop strategies to improve the patient experience among this cohort.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 544-550"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Sodium-Glucose Cotransporter-2 Inhibitors in Adults Aged ≥65 Years With Type 2 Diabetes and Cardiovascular Disease: A Cross-sectional Study of Different Drug Funding Policies","authors":"Megan L. McCreary MD ,&nbsp;Roseanne O. Yeung MD, MPH ,&nbsp;Donna P. Manca MD, MCISc ,&nbsp;Michelle Greiver MD, MSc ,&nbsp;Alexander G. Singer MB, BAO, BCh ,&nbsp;Darren Lau MD, PhD, FRCPC","doi":"10.1016/j.jcjd.2024.09.003","DOIUrl":"10.1016/j.jcjd.2024.09.003","url":null,"abstract":"<div><h3>Objectives</h3><div>Sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide heart and kidney benefits in adults with diabetes and cardiovascular disease (CVD). Public drug coverage policies for SGLT2is differ by province in Canada. In this study, we describe the potential effects of prior authorization/step therapy (PA/ST) and relatively high income-based deductibles, compared with regular benefit status with modest copay, on SGLT2i prescriptions in high-risk adults.</div></div><div><h3>Methods</h3><div>This investigation was a cross-sectional study of adults ≥65 years of age with type 2 diabetes and CVD and taking at least 1 antihyperglycemic agent from 2019 to 2020. Using electronic medical record data obtained from primary care practices, we compared SGLT2i use (2019 to 2020) in Alberta (PA/ST, modest copay) and Manitoba (PA/ST, relatively high income-based deductible) vs Ontario (regular benefit status, modest copay). Poisson regression was used to adjust for confounders, including age, sex, glycated hemoglobin, and other medication use. Other diabetes medications were estimated as control cases.</div></div><div><h3>Results</h3><div>We included 3,191 adults (average age 75 years, 31% women). SGLT2i use was lowest in Manitoba (15.6%), followed by Alberta (25.9%), and highest in Ontario (31.9%). After adjustment, compared with Ontario, SGLT2i prescriptions were lower in Alberta (prevalence ratio [PR] 0.80, 95% confidence interval [CI] 0.71 to 0.91, p&lt;0.001) and Manitoba (PR 0.48, 95% CI 0.39 to 0.59, p&lt;0.001).</div></div><div><h3>Conclusions</h3><div>PA/ST and relatively high deductibles are associated with reduced SGLT2i prescribing---PA/ST by approximately 20% in Alberta and Manitoba, and relatively high deductibles by an additional relative reduction of 40% in Manitoba. PA/ST and cost-sharing policies should be flexible and responsive to changing evidence of clinical benefit.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 524-530.e2"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rising Prevalence of Gestational Diabetes Mellitus in Ontario: A Population-based Study","authors":"Hardil A. Bhatt BSc ,&nbsp;Gillian L. Booth MD, MSc ,&nbsp;Ghazal Fazli PhD ,&nbsp;Calvin Ke MD, PhD ,&nbsp;Chris Kenaszchuk MSc ,&nbsp;Lorraine L. Lipscombe MD, MSc ,&nbsp;Sarah Mah PhD ,&nbsp;Laura C. Rosella PhD ,&nbsp;Deva Thiruchelvam MSc ,&nbsp;Baiju R. Shah MD, PhD","doi":"10.1016/j.jcjd.2024.10.001","DOIUrl":"10.1016/j.jcjd.2024.10.001","url":null,"abstract":"<div><h3>Objectives</h3><div>Gestational diabetes mellitus (GDM) is a common pregnancy complication. Studies have shown that the prevalence of GDM is rising worldwide. In this study, we aimed to describe the prevalence of GDM in Ontario, Canada, between 2015 and 2021.</div></div><div><h3>Methods</h3><div>Population-based linked health-care administrative databases were used to identify women with GDM via a validated algorithm. Age-standardized GDM prevalence was described for each year between 2015 and 2021. Crude GDM prevalence trends were stratified according to age and income, and trend over time was evaluated using negative binomial regression.</div></div><div><h3>Results</h3><div>Crude GDM prevalence was 9.5% within this period, with age-standardized prevalence increasing by 35% over the duration of the study (p&lt;0.0001). Prevalence declined in the first year of the COVID-19 pandemic, but it rose again the next year. Prevalence was directly associated with age (p&lt;0.0001) and inversely associated with income (p=0.04), but these disparities did not change over time.</div></div><div><h3>Conclusions</h3><div>GDM prevalence is rising, but the transient decline in the first year of the pandemic may reflect forgone GDM screening. Disparities in prevalence by age and income are not worsening. GDM is creating a growing burden for the health-care system, particularly for lower income individuals.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 539-543"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supported Open-source Artificial Pancreas Systems in Type 1 Diabetes With Suboptimal Glycemia","authors":"Kate Hawke MBBS, FRACP ,&nbsp;Tom Elliott MBBS, FRCPC","doi":"10.1016/j.jcjd.2024.09.002","DOIUrl":"10.1016/j.jcjd.2024.09.002","url":null,"abstract":"","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 551-553"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Qualitative Exploration of Participant Experiences in the Avoiding Diabetes After Pregnancy Trial in Moms (ADAPT-M)","authors":"Katelyn Sushko PhD ,&nbsp;Shannon Weissman MD, MSc ,&nbsp;Dominika Bhatia BSc, PhD ,&nbsp;Paige Alliston RD, MHSc ,&nbsp;Lorraine Lipscombe MD, MSc, FRCPC ,&nbsp;Diana Sherifali RN, PhD","doi":"10.1016/j.jcjd.2024.08.006","DOIUrl":"10.1016/j.jcjd.2024.08.006","url":null,"abstract":"<div><h3>Objectives</h3><div>Gestational diabetes mellitus (GDM), a temporary condition of pregnancy, identifies women at high risk of developing subsequent type 2 diabetes mellitus (T2D). Lifestyle interventions have been shown to reduce the risk of developing T2D after GDM. However, they often have low attendance and adherence rates. The Avoiding Diabetes After Pregnancy Trial in Moms (ADAPT-M) program is a 24-week, home-based postpartum program aimed at bridging the gap from prenatal care to T2D prevention for women with GDM. Our objective was to explore the experiences of participants who completed the ADAPT-M program, to elicit their perceived benefits and opportunities for improvement.</div></div><div><h3>Methods</h3><div>This was a qualitative descriptive study wherein we conducted semistructured interviews with 21 women with previous GDM who participated in the ADAPT-M program in Ontario, Canada. Transcripts were analyzed using NVivo software using a conventional content analysis approach.</div></div><div><h3>Results</h3><div>Two themes describing the experience of women who underwent the ADAPT-M lifestyle-based coaching program emerged: 1) the benefits of a supportive relationship between coaches and participants; and 2) a desire for more from the program, including peer support, more customization, and addressing emotional needs.</div></div><div><h3>Conclusions</h3><div>Our findings support the importance of fostering supportive health-care relationships in T2D prevention programs for postpartum women with a history of GDM. Enhanced customization, emotional support, and opportunities for peer support should be considered in the development of future programming to better meet the needs of participants.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 510-516.e1"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Long COVID and the Impact on Diabetes Management and Physical Activity Participation in Adults With Type 2 Diabetes: An Australia-wide Cross-sectional Online Survey","authors":"Emily R. Cox PhD ,&nbsp;Ronald C. Plotnikoff PhD ,&nbsp;Peter G. Gibson PhD ,&nbsp;Shelley E. Keating PhD ,&nbsp;Shamasunder Acharya MBBS ,&nbsp;Hayley Lewthwaite PhD","doi":"10.1016/j.jcjd.2024.08.004","DOIUrl":"10.1016/j.jcjd.2024.08.004","url":null,"abstract":"<div><h3>Objectives</h3><div>The aim of this research was to understand the prevalence and impact of long COVID on adults with type 2 diabetes (T2D). Specifically, we sought to identify the proportion of adults with T2D who have had COVID-19 and experienced long COVID symptoms. We also explored how these ongoing symptoms impact diabetes management and physical activity participation.</div></div><div><h3>Methods</h3><div>Our study was carried out using an online survey of adults in Australia with T2D who had confirmed COVID-19 ≥12 weeks before participation. Respondents were asked to report the presence (and severity) of long COVID symptoms, and, for those with long COVID, the impact of their symptoms on diabetes management (blood glucose, body weight) and physical activity participation (activities of daily living, work/study, exercise).</div></div><div><h3>Results</h3><div>Survey responses were provided by 1,046 adults with T2D (median age 61.0 [interquartile range 49.8 to 70.0] years; 56.0% men, 42.1% women, and 1% nonbinary/transgender; median T2D duration 10.0 [5.0 to 18.0] years and median time since COVID-19 infection 33.0 [20.3 to 36.1] weeks). Almost one-third (30%) of respondents reported long COVID symptoms (present ≥12 weeks after most recent infection); 40% of respondents with long COVID symptoms reported a worsening of their diabetes management since their COVID-19 infection, with 29% reporting trouble controlling their blood glucose and 43% reporting a higher body weight. Two-thirds of respondents with ongoing symptoms reported that these symptoms moderately to severely impacted their ability to perform activities of daily living, work, and/or exercise. The majority of those with long COVID reported reducing the frequency, duration, and/or intensity of exercise since their COVID-19 infection, with 36.1% not yet returning to their preinfection exercise levels; 66% cited ongoing symptoms as the primary reason for these limitations.</div></div><div><h3>Conclusions</h3><div>Physical activity is a crucial component of diabetes management. However, the high prevalence of long COVID is hindering participation in this population, as well as deleteriously impacting diabetes management. Developing strategies to support adults with T2D and long COVID to recommence safe levels of physical activity is of critical importance.</div></div>","PeriodicalId":9565,"journal":{"name":"Canadian Journal of Diabetes","volume":"48 8","pages":"Pages 493-501.e5"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142006102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}